Melissa Antonik, MD
Endocrinology, Diabetes & Metabolism · Leesburg, VANPI 1316025372
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $156, 3.2 times the $48 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in VA, where the typical reported total is $1,187.
Across 14 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$39
- Radius Health, Inc.$31
- Amgen$30
- Ascendis Pharma Endocrinology Inc$29
- Insulet Corporation$24
- Abbott$24
- plus $114 from 6 others
Across 18 payments — averaging $5391.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$97K
What the payments were for
- Food & beverage$292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $39 |
| Radius Health, Inc. | 1 | $31 |
| Amgen | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Insulet Corporation | 1 | $24 |
| Abbott | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| BETA Bionics, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $15 |
How this compares
$292 in reported general payments places this provider in the 25th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $181,489 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $127,537 |
| JardianceEmpagliflozin | 40 | $65,219 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 35 | $44,483 |
| JanuviaSitagliptin Phosphate | 24 | $40,386 |
| TrulicityDulaglutide | 11 | $24,255 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $23,838 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $22,625 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 16 | $19,411 |
| Novolog FlexpenInsulin Aspart | 20 | $9,668 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 61 | $9,196 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $8,440 |
| SynthroidLevothyroxine Sodium | 88 | $8,194 |
| Levothyroxine Sodium | 252 | $3,238 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 16 | $2,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $19 | $181,48975 claims |
| Boehringer IngelheimJardiance | $15 | $65,21940 claims |
| MerckJanuvia | $15 | $40,38624 claims |
| Lilly USA, LLCTrulicity | $22 | $24,25511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Leesburg
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.